- OsteoAdapt SP demonstrated more robust and faster bone formation than the gold standard autograft in a large animal model of spinal fusion
- The study demonstrated the safety and efficacy of AMP2 and the utility of OsteoAdapt SP at multiple dosages, in support of human IDE Phase I/II clinical studies, which are currently underway
, /PRNewswire/ — Theradaptive, a privately held, clinical stage biologics company developing targeted protein therapeutics for spine, orthopedics, soft tissue repair and targeted immuno-oncology, today announced the peer-reviewed publication of a preclinical spinal fusion study. This study features Theradaptive’s lead candidate, OsteoAdapt SP, in Spine,the preeminent journal for spinal surgeons (Volume 49, Issue 19). The study, entitled “In vivo Assessment of AMP2, a Novel Ceramic-Binding BMP-2, in Ovine Lumbar Interbody Fusion,” demonstrated the preclinical safety and efficacy of OsteoAdapt SP in a clinically relevant large animal model. Results showed faster and more robust new bone formation within …